Skip to content
DraconiticResearch
Search Sources API
210,049 studies31 sourcesUpdated 7 min ago

Oncology

5,302 studies557 in 7 days2,546 in 30 days

Filters
Type
Date
Clear

Latest

5,302 studies

  1. Experimental validation of time-driven proton PBS FLASH delivery on a clinical proton therapy system
    Dawid Krzempek, Jan Gajewski, Hubert Jabłoński +14
    Physics and Imaging in Radiation OncologyPeer-reviewedCC BY-NC-NDFull textOncologyDOAJEurope PMCEurope PMCPMC
  2. Spatial context of cellular heterogeneity in triple-negative breast cancer reveals actionable subtypes
    Zahra Mesrizadeh, Kavitha Mukund, Lu Yang +12
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxivPMC
  3. Pan-cancer remodeling of reactive oxygen species homeostasis: distinct roles of the ROS-generation and antioxidant arms in immune context and outcome
    K. Xie, Y. Xuan, R. Sun +7
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  4. Spatially resolved tumor-microenvironment architecture defines therapeutic response in unresectable hepatoblastoma
    Zahra Mesrizadeh, Mylarappa Ningappa, Sarangarajan Ranganathan +12
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxivEurope PMCPMC
  5. Decoupling of CO2 and O2 fluxes reveals oxygen-independent decarboxylation in anoxic mammalian cells
    H. Vellama, H. Eichelmann, U. Gross +2
    bioRxivPreprintCC BYFull textOncologybioRxiv
  6. MicroRNA Regulation of the Estrogen Receptor Alpha 3'UTR in Canine Mammary Tumor (CMT28) Cells.
    Deepika Goyal, Richard Curtis Bird
    Veterinary sciencesPeer-reviewedCC BYFull textOncologyEurope PMC
  7. Comparative Prognostic Value of the Preoperative Prognostic Nutritional Index and Gustave Roussy Immune Score After Curative-Intent Gastrectomy for Gastric Cancer.
    Ahmet Sencer Ergin, Mustafa Can Alıklı, Ali Karabulut +7
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  8. FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patients
    Christos Vaklavas, Saundra S. Buys, Sandra D. Scherer +13
    medRxivPreprintCC BY-NCFull textOncologymedRxivPMC
  9. More Than Half of DNMT3A-Mutant Patients in Pooled Public Cancer Genomic Data Carry No Tumor-Derived Mutation: Clonal Hematopoiesis Introduced by Patient-Keyed Aggregation
    M. Pan, L. Zhi, J. Chi +1
    medRxivPreprintCC BYFull textOncologymedRxiv
  10. A randomized controlled trial of a multidisciplinary collaborative fatigue management program for patients undergoing hematopoietic stem cell transplantation: study protocol
    Jianli Zhang, Liya Ren, Liwei Xu +5
    TrialsPeer-reviewedCC BY-NC-ND 4.0OncologyCrossref
  11. Targeting the PSGL-1 glycoprotein in cancer: cellular mechanisms and emerging immunotherapeutic strategies.
    João L Pereira, Nuno R Dos Santos
    Immunotherapy advancesPeer-reviewedCC BY-NCFull textOncologyEurope PMC
  12. Outcomes following Pancreatoduodenectomy in Patients ≥80 Years: An Analysis of the Prospective Pancreas Registry of the German Society for General and Visceral Surgery (DGAV|Registry Pancreas).
    Philipp Scherber, Sebastian Holländer, Gereon Gäbelein +14
    Visceral medicinePeer-reviewedCC BYFull textOncologyEurope PMC
  13. Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders.
    Yimei Que, Xienilai Xie, Wei Xie +5
    Journal of orthopaedic translationPeer-reviewedCC BYFull textOncologyEurope PMC
  14. Protocol for an immunocompetent KPC mouse model of pancreatic cancer resection and recurrence for perioperative treatment studies.
    Jacob L Léger, Nawal Amhis, Sarah Mansouri +5
    STAR protocolsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  15. Disability related disparities in diagnosis and survival of digestive system cancers in Northern Italy
    Flavia Pennisi, Carlotta Buzzoni, Federico Gervasi +4
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  16. Association between postoperative serum calcium and complications after pancreaticoduodenectomy in a retrospective multicenter study
    Tiantian Huang, Sicheng Pu, Wenyuan Xie +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  17. The impact of public discourse on healthcare utilization during the COVID-19 pandemic
    Julia Schilling, Esra Eren Bayindir, Robert Fuchs +1
    Scientific ReportsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  18. A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M)
    Christine A Pratilas, Marielle E Yohe, Paul M Williams +20
    The OncologistPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  19. PET imaging enables direct evaluation of ferroptosis in HCC synergistically induced by anti-PD-L1 and Olaparib
    Feng Xiong, Cheng Xu, Pei Wang +9
    Experimental & Molecular MedicinePeer-reviewedCC BY 4.0Full textOncologyPMC
  20. IGF2BP2 remodels the lung metastatic immune microenvironment to promote bladder cancer metastasis
    Ming Bai, Tianyao Liu, Hao Wu +19
    Cellular and Molecular ImmunologyPeer-reviewedLicence not statedFull textOncologyPMC
  21. Comprehensive landscape and future perspectives of PIWI-interacting RNAs in cancer (Review)
    Xiaoqian Yu, Changlong Li, Tongtao Zhuang +5
    International Journal of OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  22. Assessment of a direct fluorescence-based cell-free DNA assay for evaluating the extent of metastatic dissemination: An exploratory study
    Jae-Joon Kim, Yangjeong Lee, Yun Jeong Hong +1
    Biomedical ReportsPeer-reviewedLicence not statedFull textOncologyPMC
  23. Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity
    John H. Klich, Anahita Nejatfard, Emily L. Meany +4
    Cell Reports MedicinePeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  24. Bioenergetic and Proteomic Profiling of ARID1A-Deficient Ovarian Clear Cell Carcinoma under Metabolic Challenge
    Harith A. Ismail, Kristina Dankova, Trudy J. Philips +13
    bioRxivPreprintCC BYFull textOncologybioRxivEurope PMCPMC
  25. Malignant and stromal partial EMT programmes and cetuximab outcome in head and neck cancer
    D. Z. R. Alkhatib, S. Lunetto, P. Chakraborty +5
    bioRxivPreprintCC BYFull textOncologybioRxiv